Clinical Trial

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Name: Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea — clinical trial record (NCT06928818)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-04-07; most recent amendment 2026-04-21.

Trial Details

NCT Number	NCT06928818
Lead Sponsor	Seoul National University Hospital
Conditions	Cancer of Breast, Trastuzumab Emtansine, Trastuzumab Deruxtecan
Enrollment	100 participants
Start Date	2025-02-26
Primary Completion	2028-09-30 (estimated)
Study Completion	2029-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-23